SCHEMBL3560935

SCHEMBL3560935

CCc1ccc(S(=O)(=O)N(C)C2CCN(CCNC(=O)Nc3cc(C)nc(C)c3)CC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.53
HTR2C P28335 3/20 0.53
NAMPT P43490 4/20 0.47
L3MBTL1 Q9Y468 2/20 0.46
POLB P06746 2/20 0.45
MEN1 O00255 1/20 0.44
TP53 P04637 1/20 0.44
ALOX15 P16050 1/20 0.44
KMT2A Q03164 1/20 0.44
RXFP1 Q9HBX9 1/20 0.42
APOBEC3A P31941 3/20 0.42
APOBEC3G Q9HC16 3/20 0.42
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CCR3 P51677 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
UTS2R Q9UKP6 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3563376 0.92 HTR2A (0.51) HTR2AHTR2CNAMPTL3MBTL1POLB
SCHEMBL3562731 0.91 POLB (0.45) HTR2AHTR2CNAMPTPOLBMEN1
SCHEMBL3564148 0.91 NAMPT (0.49) HTR2AHTR2CNAMPTPOLBMEN1
SCHEMBL3565139 0.90 L3MBTL1 (0.59) NAMPTL3MBTL1POLBAPOBEC3AAPOBEC3G
SCHEMBL3561910 0.90 HTR2A (0.51) HTR2AHTR2CNAMPTL3MBTL1MEN1
SCHEMBL3554924 0.90 L3MBTL1 (0.51) HTR2AHTR2CNAMPTL3MBTL1TP53
SCHEMBL3565549 0.90 HTR2A (0.49) HTR2AHTR2CNAMPTL3MBTL1POLB
SCHEMBL3562435 0.89 L3MBTL1 (0.53) HTR2AHTR2CNAMPTL3MBTL1POLB
SCHEMBL3565128 0.89 HTR2A (0.53) HTR2AHTR2CNAMPTL3MBTL1POLB
SCHEMBL3568175 0.87 L3MBTL1 (0.43) HTR2AHTR2CNAMPTL3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7750161-B2 Pyridine derivatives ACTELION PHARMACEUTICALS, LTD. (CH) 2010-07-06 US claimed
EP-1670470-B1 PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2009-04-08 EP claimed
US-20070043081-A1 Novel pyridine derivatives ACTELION PHARMACEUTICALS, LTD. (CH) 2007-02-22 US claimed
EP-1670470-B1 PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2009-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070043081-A1 Novel pyridine derivatives P2RY4, P2RX6, P2RX4 HTR2A 119/4885HTR2C 92/4885NAMPT 245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.